These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 20481655)

  • 1. Castration-resistant prostate cancer: current and emerging treatment strategies.
    Di Lorenzo G; Buonerba C; Autorino R; De Placido S; Sternberg CN
    Drugs; 2010 May; 70(8):983-1000. PubMed ID: 20481655
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The treatment of castration-resistant prostate cancer].
    Petrányi Á
    Magy Onkol; 2012 Dec; 56(4):219-28. PubMed ID: 23236591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel options for the treatment of castration-resistant prostate cancer.
    Ohlmann CH; Merseburger AS; Suttmann H; Schilling D; Trojan L; Kempkensteffen C; Corvin S; Mathers MJ; Bastian PJ
    World J Urol; 2012 Aug; 30(4):495-503. PubMed ID: 22101903
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medical strategies for treatment of castration resistant prostate cancer (CRPC) docetaxel resistant.
    Altavilla A; Iacovelli R; Procopio G; Alesini D; Risi E; Campennì GM; Palazzo A; Cortesi E
    Cancer Biol Ther; 2012 Sep; 13(11):1001-8. PubMed ID: 22825325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New perspectives in the therapy of castration resistant prostate cancer.
    Rescigno P; Buonerba C; Bellmunt J; Sonpavde G; De Placido S; Di Lorenzo G
    Curr Drug Targets; 2012 Dec; 13(13):1676-86. PubMed ID: 23043326
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current and emerging treatments in the management of castration-resistant prostate cancer.
    Shapiro D; Tareen B
    Expert Rev Anticancer Ther; 2012 Jul; 12(7):951-64. PubMed ID: 22845410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Castration-refractory prostate cancer: New drugs in the pipeline.
    Schrijvers D; Van Erps P; Cortvriend J
    Adv Ther; 2010 May; 27(5):285-96. PubMed ID: 20532721
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New developments in castrate-resistant prostate cancer.
    Shore N; Mason M; de Reijke TM
    BJU Int; 2012 Jun; 109 Suppl 6():22-32. PubMed ID: 22672122
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies.
    Crawford ED; Higano CS; Shore ND; Hussain M; Petrylak DP
    J Urol; 2015 Dec; 194(6):1537-47. PubMed ID: 26196735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cabazitaxel for the treatment of prostate cancer.
    Michielsen DP; Braeckman JG; Denis L
    Expert Opin Pharmacother; 2011 Apr; 12(6):977-82. PubMed ID: 21406025
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New therapeutics to treat castrate-resistant prostate cancer.
    Acar O; Esen T; Lack NA
    ScientificWorldJournal; 2013; 2013():379641. PubMed ID: 23781155
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New agents for prostate cancer.
    Agarwal N; Di Lorenzo G; Sonpavde G; Bellmunt J
    Ann Oncol; 2014 Sep; 25(9):1700-1709. PubMed ID: 24658665
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New treatment options for castration-resistant prostate cancer.
    Simondsen K; Kolesar J
    Am J Health Syst Pharm; 2013 May; 70(10):856-65. PubMed ID: 23640346
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Strategy in advanced castration-resistant prostate cancer].
    Gross-Goupil M; Roca S; Pasticier G; Ravaud A
    Bull Cancer; 2012 Jul; 99 Suppl 1():S37-45. PubMed ID: 22522582
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent advances in second-line treatment of castration-resistant prostate cancer.
    Ong M; Winquist E
    Curr Opin Support Palliat Care; 2011 Sep; 5(3):199-205. PubMed ID: 21734586
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [New drugs in metastatic castration-resistant prostate cancer].
    Albiges L; Loriot Y; Gross-Goupil M; de La Motte Rouge T; Blesius A; Escudier B; Massard C; Fizazi K
    Bull Cancer; 2010 Jan; 97(1):149-59. PubMed ID: 20022854
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimizing the care of patients with advanced prostate cancer in the UK: current challenges and future opportunities.
    Payne H; Bahl A; Mason M; Troup J; De Bono J
    BJU Int; 2012 Sep; 110(5):658-67. PubMed ID: 22429837
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Castration resistant prostate cancer (CRPC): state of the art, perspectives and new challenges.
    Massari F; Maines F; Modena A; Brunelli M; Bria E; Artibani W; Martignoni G; Tortora G
    Anticancer Agents Med Chem; 2013 Jul; 13(6):872-86. PubMed ID: 23272970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New therapies for castration-resistant prostate cancer: efficacy and safety.
    Beltran H; Beer TM; Carducci MA; de Bono J; Gleave M; Hussain M; Kelly WK; Saad F; Sternberg C; Tagawa ST; Tannock IF
    Eur Urol; 2011 Aug; 60(2):279-90. PubMed ID: 21592649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
    Mottet N; Bellmunt J; Bolla M; Joniau S; Mason M; Matveev V; Schmid HP; Van der Kwast T; Wiegel T; Zattoni F; Heidenreich A
    Eur Urol; 2011 Apr; 59(4):572-83. PubMed ID: 21315502
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.